Liu Q, Nakae I, Takahashi M, Takaoka A, Kinoshita M
First Department of Internal Medicine, Shiga University of Medical Science, Ohtsu, Japan.
Cardiovasc Drugs Ther. 1996 Mar;10(1):23-30. doi: 10.1007/BF00051127.
Tilisolol is a beta-blocking agent with vasodilatory properties that was recently shown to possess a potassium (K+) channel opening activity. We investigated whether tilisolol has vasodilatory effects on coronary circulation in dogs. Mongrel dogs were chronically instrumented for measurements of circumflex coronary artery diameter (CoD) and coronary blood flow (CBF). We compared the effects of tilisolol on dog coronary arteries with those of two beta-blockers, propranolol and arotinolol. Both propranolol (1 mg/kg, intravenously, i.v.) and arotinolol (0.25 mg/kg, i.v.) decreased CoD and increased coronary vascular resistance (CVR). Tilisolol (2 mg/kg, i.v.) decreased CVR but had no significant effect on CoD. To investigate the mechanism of the coronary action of tilisolol, we examined differences in the response to tilisolol in the absence and presence of glibenclamide, an ATP-sensitive K+ channel blocker. Tilisolol (1,2,4, and 8 mg/kg, i.v.) produced a dose-dependent decrease in CVR without glibenclamide, whereas pretreatment with glibenclamide significantly suppressed this effect. Without glibenclamide, tilisolol had no significant effect on CoD at doses of 1-4 mg/kg (i.v.). However, at the higher dose of 8 mg/kg (i.v.), tilisolol significantly increased CoD (1.00 +/- 0.15%, p < 0.01). After pretreatment with glibenclamide, tilisolol (1-8 mg/kg, i.v.) produced a significant decrease in CoD. Therefore, we concluded that tilisolol exerts its vasodilatory effect on the coronary circulation through an ATP-sensitive K+ channel opening mechanism, and that its vasodilatory action is more prominent in coronary resistance vessels than in large coronary arteries.
替利洛尔是一种具有血管舒张特性的β受体阻滞剂,最近发现它具有钾(K+)通道开放活性。我们研究了替利洛尔对犬冠状动脉循环是否具有血管舒张作用。用杂种犬进行长期实验,以测量左旋冠状动脉直径(CoD)和冠状动脉血流量(CBF)。我们将替利洛尔对犬冠状动脉的作用与两种β受体阻滞剂普萘洛尔和阿罗洛尔的作用进行了比较。普萘洛尔(1mg/kg,静脉注射,i.v.)和阿罗洛尔(0.25mg/kg,i.v.)均使CoD减小,冠状动脉血管阻力(CVR)增加。替利洛尔(2mg/kg,i.v.)使CVR降低,但对CoD无显著影响。为了研究替利洛尔冠状动脉作用的机制,我们研究了在不存在和存在格列本脲(一种ATP敏感性K+通道阻滞剂)的情况下对替利洛尔反应的差异。替利洛尔(1、2、4和8mg/kg,i.v.)在不存在格列本脲时使CVR呈剂量依赖性降低,而用格列本脲预处理可显著抑制这种作用。在不存在格列本脲时,替利洛尔在1-4mg/kg(i.v.)剂量下对CoD无显著影响。然而,在8mg/kg(i.v.)的较高剂量下,替利洛尔使CoD显著增加(1.00±0.15%,p<0.01)。用格列本脲预处理后,替利洛尔(1-8mg/kg,i.v.)使CoD显著降低。因此,我们得出结论,替利洛尔通过ATP敏感性K+通道开放机制对冠状动脉循环发挥血管舒张作用,并且其血管舒张作用在冠状动脉阻力血管中比在大冠状动脉中更显著。